Business
Teknova Expands Proprietary AAV-Tek™ Solutions Product Line to Deliver End-to-End Solutions for Gene Therapy Process Development
First-of-its-kind screening kit now available for AAV8 – along with a suite of high-quality reagents to support the entire AAV workflow – helping gene therapy
About this update from Alpha Teknova, Inc.
[{"type":"text","content":"First-of-its-kind screening kit now available for AAV8 – along with a suite of high-quality reagents to support the entire AAV workflow – helping gene therapy developers save months in process development\nHOLLISTER, Calif., July 11, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today launched the next set of reagents in the Company’s proprietary product line, AAV-Tek™ Solutions. Available for purchase starting today is a version of Teknova’s AAV-Tek AEX Buffer Screening Kit for the AAV8 serotype, along with a suite of reagents to support the entire gene therapy workflow. “After we introduced our first proprietary gene therapy product a few months ago – the AAV-Tek AEX Buffer Screening Kit for AAV2 – customers encouraged us to create additional solutions to better support AAV gene therapy developers,” said Stephen Gunstream, Teknova’s President and Chief Executive Officer. “In a few short months, our talented team has delivered the AEX Buffer Screening Kit for AAV8, specifically designed to help gene therapy developers save months in process development time. We’re also making available more than 20 additional reagents we’ve identified as key solutions to support the entire gene therapy workflow. We are uniquely positioned to address key bioprocessing bottlenecks and streamline the manufacturing process through a combination of new, proprietary products and off-the-shelf, proven reagents, as we help our gene therapy customers seamlessly scale from process development to clinical production.” The AAV-Tek AEX Buffer Screening Kit was created to help streamline the identification of the ideal buffer formulation for use during AAV downstream processing, specifically during the anion exchange (AEX) purification step. Developed by Teknova’s Research and Development team, the kit addresses critical pain points in the workflow by providing a selection of serotype-specific equilibration and elution buffers to optimize the separation of empty and full capsids during polishing. Teknova conducted a robust design of experiments across multiple AAV serotypes by monitoring four different critical quality attributes (infectivity, recovery, purity, and peak sep...